Glaukos touts IOP, medication use reductions in iStent trial

Glaukos (NYSE:GKOS) today released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use. The San Clemente, Calif.-based company’s iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP. Results were published in the January issue of the Journal of Glaucoma. “Although the iStent is currently indicated for use in the United States during cataract surgery in mild to moderate glaucoma patients, this study offers important insights into the potential for ourtechnology platform to ultimately serve a full range of glaucoma disease states and progression,” prez &CEO Thomas Burns said in a prepared statement. Data in the study came from 59 glaucomatous eyes with cataracts and severe visual field loss, recording a baseline medicated mean IOP of 19.3 mm Hg and mean topical glaucoma medication use per eye of 2.3. A total of 49 eyes were followed out to two years after implantation, with mean postoperative IOP decreasing to 14.9 mm Hg and mean glaucoma medication use dropping to 1.6. IOP reduction was maintained in a consistent cohort of 32 eyes with data available through three years, with a postoperative IOP of 14.1, down from 18...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news

Related Links:

Light-Induced Pupillary Responses in Alzheimer's Disease Pratik S. Chougule1, Raymond P. Najjar1,2, Maxwell T. Finkelstein1, Nagaendran Kandiah3,4 and Dan Milea1,2,5* 1Department of Visual Neurosciences, Singapore Eye Research Institute, Singapore, Singapore 2The Ophthalmology &Visual Sciences ACP, Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore 3Department of Neurology, National Neuroscience Institute, Singapore, Singapore 4Duke-National University of Singapore (NUS), Singapore, Singapore 5Singapore National Eye Centre, Singapore, Singapore The impact of Alzheimer&...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Discussion Suppressor of cytokine signaling 1 is an essential molecule for maintaining immune homeostasis and subverting inflammation. Disorders arising from excess inflammation or SOCS1 deficiency can be potentially treated with SOCS1 mimetics (Ahmed et al., 2015). While SOCS1 has promising potential in many disorders, it should be noted that new targets and actions of SOCS1 are still being discovered and not all the effects of this protein are beneficial in autoimmune diseases and cancer. For instance, SOCS1 degrades IRS1 and IRS2, required for insulin signaling, via the SOCS Box domain, thus, limiting its potential in ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Glaukos is probably at the top of its game when it comes down to maintaining a presence in the micro-invasive glaucoma surgery (MIGS) market. The San Clemente, CA-based company reaffirmed its laser-like focus on the market during a presentation at the 37th annual J.P. Morgan Healthcare Conference earlier on Wednesday. Glaukos’ CEO Thomas Burns began his presentation speaking on the strengths of the firm and its goals going forward. “Our mission is aspirational,” Burns said. “As a company we are seeking to transform glaucoma therapy, and in doing so we ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Glaukos (NYSE:GKOS) said today it won FDA premarket approval for its iStent inject trabecular micro-bypass system. With the clearance, the iStent inject is now indicated for use in the reduction of intraocular pressure in adults with mild to moderate primary open-angle glaucoma who are undergoing concomitant cataract surgery. San Clemente, Calif.-based Glaukos said the iStent inject is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It uses a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecu...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Pre-Market Approval (PMA) Regulatory/Compliance Glaukos Source Type: news
Glaukos (NYSE:GKOS) today released two-year data from the FDA investigational device exemption pivotal trial of its iStent inject trabecular micro-bypass system, and announced a patent infringement suit it filed against Ivantis. Results of the 505-patient study were presented at the American Society of Cataracts and Refractive Surgery annual meeting by Dr. Thomas Samuelson of the Minnesota Eye Consultants, the San Clemente, Calif.-based company said. The iStent inject trabecular micro-bypass system is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It uses a pa...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Optical/Ophthalmic Patent Infringement Glaukos Source Type: news
Ophthalmic device developers Glaukos (NYSE:GKOS) and Staar Surgical (NSDQ:STAA) this week posted fourth quarter and full fiscal year 2017 earnings that beat the streets, though only Glaukos has seen its shares rise in response. San Clemente, Calif.-based Glaukos posted profits of $1 million, or 3¢ per share, on sales of $41.7 million for the three months ended December 31, seeing the bottom-line grow 650.7% while sales grew 25.6% compared with the same period during the prior year. Earnings per share were ahead of the break-even consensus on Wall Street, where analysts were expecting to see sales of $40...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Glaukos STAAR Surgical Co Source Type: news
Glaukos (NYSE:GKOS) said today that it filed for pre-market approval from the FDA of its iStent Inject trabecular micro-bypass stent for treating glaucoma. San Clemente, Calif.-based Glaukos said the device is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It used a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecular meshwork locations via a single corneal entry point. “This PMA submission marks a significant milestone for Glaukos as we continue to deliver our deep pipeline of n...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Source Type: news
Conclusions: LCT proved to be the best option for treating corneal thinning. AMT represents an alternative that allows good visual recovery but does not restore corneal thickness as efficiently as LCT.
Source: Cornea - Category: Opthalmology Tags: Clinical Science Source Type: research
Glaukos (NYSE:GKOS) said today it created a direct sales organization to commercially launch its iStent inject trabecular micro-bypass stent for alleviating intra-ocular pressure. The iStent Inject is made from non-ferromagnetic titanium and coated in heparin, designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. “The advent of Micro-Invasive Glaucoma Surgery, or MIGS, is revolutionizing the way we treat glaucoma patients and the commercial launch of iStent inject in Canada underscores the continuing advance of this excitin...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Optical/Ophthalmic Stents Glaukos Corp. Source Type: news
Glaukos (NYSE:GKOS) said it submitted an Investigational New Drug application to the FDA for its Travoprost intraocular implant delivered with the company’s iDose delivery system to reduce elevated intraocular pressure in patients with glaucoma. The Travoprost intraocular implant is injected through a clear corneal incision and secured in the anterior chamber, where the iDose system provides continuously elutes therapeutic levels of medication for an extended period of time, Glaukos said. “This IND submission represents a seminal milestone, which the Glaukos team achieved well ahead of our origin...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Corp. Source Type: news
More News: Burns | Cataract Removal | Cataracts | Clinical Trials | Eye Implants | Eyes | Glaucoma | Opthalmology | Study | Travatan | USA Health